Pfizer/BioNTech say final results show vaccine 95% effective | Inquirer News

Pfizer/BioNTech say final results show vaccine 95% effective

/ 09:19 PM November 18, 2020

Washington, United States — Pfizer and BioNTech said Wednesday that a completed study of their experimental COVID-19 vaccine showed it was 95 percent effective.

They said the two-dose vaccine had no serious safety concerns and that the companies will apply for emergency use authorization from US regulators “within days.”

The announcement came as coronavirus cases are surging in the US and other parts of the world, and boosted hopes for an end to the pandemic that has upended life around the globe.

ADVERTISEMENT

“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” said Pfizer CEO Albert Bourla.

FEATURED STORIES

“With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world,” he added.

Pfizer had said last week after a preliminary analysis that its product was more than 90 percent effective.

On Monday another biotech firm involved in the race to develop a vaccine, Moderna, said its own vaccine was 94.5 percent effective, according to a preliminary analysis.

Pfizer has previously said it expected to contact the US Food and Drug Administration to apply for an Emergency Use Authorization by the third week of November.

The FDA had imposed a requirement on COVID-19 vaccine makers of having at least two months of follow-up with volunteers after their second dose, taken 28 days after the first, in order to ensure the drugs are safe.

Moderna developed its vaccine along with the US National Institutes for Health.

ADVERTISEMENT

Both vaccines use mRNA (messenger ribonucleic acid) technology to deliver genetic material to the body that makes human cells create a protein from the virus.

This trains the immune system to be ready to attack if it encounters SARS-CoV-2, the new coronavirus strain that causes COVID-19.

Other vaccines that are in late-stage trials, such as one being developed by Johnson & Johnson and another by Oxford University and AstraZeneca, use modified viruses to deliver genetic material for the same purpose.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

No mRNA vaccines have ever been approved, but Anthony Fauci, the United States’ top infectious disease scientist, told AFP Tuesday the technology had now “established itself.”

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: 2019-nCoV, BioNTech, China, Coronavirus, COVID-19, Health, NcoV, nCoV update, News, Outbreak, pandemic, Pfizer, vaccine, Virus, world, world news, Wuhan

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.